In cooperation with the World Diabetes Foundation and the Ministry of Health of Armenia, the Armenian EyeCare Project is implementing a nationwide screening program using state-of-the-art AI technology. 350 patients …
Dr. Srinivas Sadda of Doheny Eye Institute presented new research at AAO 2019 that shows that EyeArt®, an automated, artificial intelligence (AI) screening system accurately detects diabetic retinopathy 95.5 percent …
New research shows that an automated, artificial intelligence (AI) screening system accurately detects diabetic retinopathy 95.5 percent of the time. The system doesn’t require the input of an expert ophthalmologist …
LOS ANGELES, Oct. 10, 2019 – Imagine if the very first signs of dementia, before any significant memory or other physiological changes are apparent, could be identified via a simple …
Landmark Study of Over 100,000 Diabetes Patient Visits Published in the Journal Diabetes Technology and Therapeutics Validates the Prowess of the EyeArt AI System for Diabetic Retinopathy Screening LOS ANGELES, …
July 30, 2019. Chicago, IL: The results of a prospective study, titled “Artificial Intelligence Screening for Diabetic Retinopathy: Analysis from a Pivotal Multi-center Prospective Clinical Trial,” were presented at the …
Strong EyeArt® Accuracy Results Presented by Professor Jennifer Lim at ASRS 2019 Read More »
LOS ANGELES, June 5, 2019 – Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today …
LOS ANGELES, CA, May 16, 2019 – Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced …
LOS ANGELES–(BUSINESS WIRE)–Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today that it will release results …
LOS ANGELES, Calif., April 28, 2019 – Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced …
APRIL 11 2019, LOS ANGELES–(BUSINESS WIRE)–Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today the …
Combining the high accuracy of AI disease detection with the accepted practice of human grading, the EyeScreen™ Service for diabetic retinopathy (DR) identifies cases of referable DR in any clinical …
EyeScreen™ Human+AI Diagnostic Service to be launched at ATA 2019 Read More »
Eyenuk’s logo was originally conceived back in early 2013 , to give the viewer the impression of staring at a “real” 3-dimensional eye, while giving it an orange hue to …
Eyenuk Inc., a global artificial intelligence (AI) medical technology company, is pleased to announce that it has successfully cleared an independent HIPAA audit. As a leader in real-world AI eye …
Eyenuk successfully clears HIPAA audit by A-Lign Read More »
LOS ANGELES, California, Oct. 2, 2018 – Eyenuk, Inc. announces its expansion into Germany with the adoption of EyeArt® artificial intelligence (AI) technology for the screening of diabetic retinopathy at …
A new study published in the international ‘Eye’ journal (Springer Nature) demonstrated very high sensitivity for detecting any diabetic retinopathy (95.8%) and sight-threatening diabetic retinopathy (99.1%) using EyeArt™ automated screening software with Remidio Fundus …
Eyenuk’s quality management system has been registered under the Medical Device Single Audit Program (“MDSAP”) as conforming to the requirements of ISO 13485:2003, after successfully completing an audit for the …
There is a lot of talk about the use of “deep learning” in the screening and identification of diabetic retinopathy (DR) lately. “Deep learning” is familiar to many in the …
Eyenuk Inc. is presenting a validation study titled “Automated diabetic retinopathy screening: large-scale study on consecutive patient visits in a primary care setting” at the 52nd EASD Annual Meeting in Munich, Germany. Details …
EASD 2016 in Munich: EyeArt™ 2.0 validation on over 78,685 consecutive patient cases Read More »
Eyenuk, Inc. will be showcasing its CE marked EyeArt™ fully-automated DR screening product at the 52nd EASD Annual Meeting in Munich, Germany from 12-16 September, 2016. Come visit our booth at the ICM Messe München, Messegelände, …
